3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
4
Plasma cell
2
Lymphoid
2
Genitourinary
2
Tumor-Agnostic
1
Other neoplasm
1
Other
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Classical hematology
1
Conditions
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Prostatic Neoplasms
1
Nephrolithiasis
1
Kidney Neoplasms
1
Inflammation
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Morphine
×
Genitourinary
×
Clear all
NCT06349668
2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3
Recruiting
220 enrolled
NCT01367418
2012-03-19
AIMS
Örebro University, Sweden
Phase 3
Completed
26 enrolled